Breast Cancer Clinical Trial

Predicting Pathological Response Within the 1st Week of Chemotherapy Using Diffuse Optical Spectroscopic Imaging

Summary

Women with Breast Cancer who do not respond to chemotherapy may undergo months of treatment with little or no change in tumor size or overall outcome.

The Researchers have demonstrated a previously undescribed "metabolic flare" response observed very early in neoadjuvant treatment in breast cancer patients. The research can determine that this flare is predictive of overall therapy response and is due to both an inflammatory reaction and cell death induced by cytotoxic therapy.

View Full Description

Full Description

The researcher can use Diffuse Optical Spectroscopic Imaging device to measure and predict the markers of the response in the first weeks of chemo-therapy.

The oxyhemoglobin flare response can predictive of overall pathological response to chemotherapy in human subjects. These vascular changes can indicate the rapid transient increase and then decrease in oxyhemoglobin concentration in the first hours and days after therapeutic administration. The magnitude and time course of the flare response in patients receiving cytotoxic therapy will differ between pathological responders and non-responders. This oxyhemoglobin "flare response" can be observed In tumors where vascular dynamics are intact.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Female, not pregnant, not breastfeeding
greater than 21 years of age but less than 75 years of age
will be receiving neoadjuvant chemotherapy for breast cancer as prescribed by their oncologist

Exclusion Criteria:

Under 21 year of age
Female pregnant or breastfeeding

Study is for people with:

Breast Cancer

Study ID:

NCT01277263

Recruitment Status:

Withdrawn

Sponsor:

University of California, Irvine

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Pacific Breast Care Medical Clinic
Costa Mesa California, 92627, United States
Beckman Laser Institute
Irvine California, 92612, United States
Chao Family Comprehensive Cancer Center, UCIMC
Orange California, 92868, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Study ID:

NCT01277263

Recruitment Status:

Withdrawn

Sponsor:


University of California, Irvine

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider